Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

In 5-year follow-up of RCT (n=870), 1-year of adjuvant dabrafenib plus trametinib resulted in longer duration of survival without relapse or distant metastasis than placebo (52% vs 36% alive without relapse; HR 0.51; 95% CI, 0.42 to 0.61) with no apparent long-term toxic effects.


New England Journal of Medicine